Research & Insights
Frameworks

Reading Non-GAAP Earnings: A Checklist to Avoid Getting Fooled

By Jeremy Browder · Senior Equity Research EditorUpdated ~4 min read
Non-GAAPAccountingEarnings Quality

Every quarter, the headline EPS number a company brags about in its press release is almost never the GAAP number. It's an "adjusted" or "non-GAAP" figure — management's preferred version of reality. Sometimes those adjustments are reasonable. Sometimes they're a magic trick. Your job is to know the difference in under ten minutes.

This is a checklist you can run on any earnings release before deciding whether the "beat" is real.

What non-GAAP earnings actually are

GAAP (Generally Accepted Accounting Principles) is the rulebook. It's standardized, audited, and comparable across companies. Non-GAAP is whatever management decides to show you after stripping out items they argue aren't representative of the business — typically stock-based compensation (SBC), amortization of acquired intangibles, restructuring charges, and litigation settlements.

The SEC allows non-GAAP reporting but requires a reconciliation table. That table — usually buried near the back of the press release — is the single most important page in any earnings document.

Management's argument is that non-GAAP shows the "true" earnings power of the ongoing business. That's sometimes true. It's also true that non-GAAP EPS has run higher than GAAP EPS for the S&P 500 in recent years, and the gap widens during stressed quarters. That asymmetry should make you suspicious.

The five adjustments to scrutinize first

Not all add-backs are equal. Here's how to triage them.

1. Stock-based compensation (SBC). This is the big one. When a company adds SBC back to earnings, it's treating equity grants as if they were free. They aren't — they dilute you. A useful sanity check: compare diluted share count year-over-year. If shares outstanding are growing 2-4% annually and the company is calling SBC a non-cash, non-recurring item, that's a contradiction. Tech and biotech are the worst offenders. Treat SBC add-backs as effectively fake.

2. Amortization of acquired intangibles. Companies argue this is a non-cash accounting artifact of past M&A. Fair enough — but only if you also acknowledge they paid real cash for those acquisitions. If you exclude the amortization, you should also be asking whether the deals are earning their cost of capital. Acceptable to add back, but pair it with a hard look at goodwill on the balance sheet.

3. Restructuring charges. One-time? Or one-time every year? Run a five-year search of the company's filings for "restructuring." If it appears every single year, it's not a one-time item — it's a recurring cost of doing business that management has labeled non-recurring.

4. Litigation and legal settlements. Same logic. A single multi-hundred-million settlement is plausibly extraordinary. A pattern of legal charges every year (common in pharma, finance, and big tech) is operating cost.

5. "Transformation," "integration," or "transition" costs. These vague buckets are red flags. The vaguer the label, the more skeptical you should be. Ask: what would this company look like if it stopped "transforming" for two quarters?

How to read the reconciliation table in 10 minutes

Open the earnings press release. Skip to the reconciliation of GAAP to non-GAAP net income. Then do this:

  • Sum the add-backs as a percentage of GAAP net income. If non-GAAP earnings are 50%+ higher than GAAP, you're being asked to ignore a lot. Demand a good reason.
  • Compare this quarter's add-backs to the same quarter last year. Are the same items showing up? "Non-recurring" items that recur every Q3 aren't non-recurring.
  • Cross-check against cash flow. Look at operating cash flow and free cash flow. If non-GAAP earnings are surging but FCF is flat or down, the adjustments aren't translating into actual money. Cash flow is much harder to manipulate than earnings.
  • Check diluted share count trend. If non-GAAP EPS grew 15% but share count grew 4%, the per-share story is weaker than the headline.
  • Read the footnotes. Companies occasionally change what they include in non-GAAP. A redefinition mid-year is a major yellow flag.

Sector context: where non-GAAP is more (and less) reliable

Non-GAAP is most useful in industries with heavy non-cash charges that genuinely distort the income statement: serial acquirers with large amortization (think Constellation Software, Roper), or biotech with episodic R&D milestone payments.

It's most abused in software and high-growth tech, where SBC can run 15-25% of revenue. Companies like Snowflake, Palantir (historically), and many SaaS names have shown non-GAAP profits while remaining deeply GAAP-unprofitable for years. That's not necessarily a sell signal — but you should value them on GAAP earnings or, better, on free cash flow per share, not on the adjusted figure.

Financials and REITs use their own conventions (FFO for REITs, tangible book value for banks) that operate on similar logic. The same skepticism applies.

What to watch next

  • Pull up the next earnings release you read and run the five-adjustment triage above before reacting to the headline. It takes less than ten minutes.
  • Build a simple spreadsheet tracking GAAP EPS, non-GAAP EPS, and FCF per share for your top holdings. A widening gap between non-GAAP and FCF is a quality-of-earnings warning.
  • Watch for definitional changes. If a company expands what it excludes from non-GAAP this quarter versus last year, read the explanation carefully — and discount it.
  • Anchor your valuation to GAAP earnings or free cash flow. Use non-GAAP as supplementary context, never as the primary lens. The companies that survive multi-year drawdowns are the ones where the GAAP and non-GAAP stories eventually converge.

Related research

FrameworksMay 25, 2026
Segment Reporting Changes: What Management Is Hiding

When a company restructures its segment reporting, it's rarely cosmetic. Here's a framework for spotting what's being buried — and what to do about it.

FrameworksMay 25, 2026
When to Trim a Winner: A Three-Lens Framework

Trimming a winner is harder than buying one. Here's how to separate thesis decay, valuation stretch, and position-size risk — and act on the right one.

FrameworksMay 25, 2026
ISM and PMI as Stock Signals: Which Sectors Lead and Lag

A practical framework for reading ISM Manufacturing PMI as an equity signal — which sectors front-run the cycle, which lag, and how to use the 50 line.